Zobrazeno 1 - 10
of 18
pro vyhledávání: '"O. Alejandro Balbin"'
Autor:
Joanne Chiu, Fei Su, Mukta Joshi, Norikazu Masuda, Takashi Ishikawa, Tomoyuki Aruga, Juan Pablo Zarate, Naveen Babbar, O. Alejandro Balbin, Yoon-Sim Yap
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-13 (2023)
Abstract Background There is increasing interest in the use of liquid biopsies, but data on longitudinal analyses of circulating tumor DNA (ctDNA) remain relatively limited. Here, we report a longitudinal ctDNA analysis of MONALEESASIA, a phase Ib tr
Externí odkaz:
https://doaj.org/article/5e86dee618714747b7670dcba6041b8f
Autor:
Lauren Fairchild, Jeanne Whalen, Katie D’Aco, Jincheng Wu, Carroll B. Gustafson, Nadia Solovieff, Fei Su, Rebecca J. Leary, Catarina D. Campbell, O. Alejandro Balbin
Publikováno v:
Science Translational Medicine. 15
In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for gen
Autor:
Dejan Juric, Nicholas Turner, Aleix Prat, Stephen Chia, Eva M Ciruelos, Manuel Ruiz-Borrego, Pamela Drullinsky, Florence Lerebours, Thomas Bachelot, O. Alejandro Balbin, Mukta Joshi, Estelle Roux, Christina H Arce, Murat Akdere, Hope S Rugo
Publikováno v:
Cancer Research. 82:P5-13
Introduction: Alpelisib (ALP, a PI3Kα inhibitor and degrader) + ET has demonstrated efficacy in patients (pts) with HR+, HER2-, PIK3CA-mutated ABC progressing on/after CDK4/6i + ET in the ongoing Phase II BYLieve study (NCT03056755). The primary end
Autor:
Luojun Victor Wang, Yvonne Y. Lau, Thomas John, Giovanni Selvaggi, Filippo de Braud, Jeffrey W. Scott, Enriqueta Felip, Vanessa Giannone, O. Alejandro Balbin, Michela Maur, Daniel Shao-Weng Tan, Pilar Cazorla, Martijn P. Lolkema, Herbert H. Loong, Johan Vansteenkiste, Alice T. Shaw, Jason Baum, Geoffrey Liu
Publikováno v:
Journal of Thoracic Oncology, 15(3), 392-403. International Association for the Study of Lung Cancer
Scientia
Scientia
INTRODUCTION: Induction of programmed death ligand 1 (PD-L1) expression due to constitutive oncogenic signaling has been reported in NSCLC models harboring echinoderm microtubule associated protein like 4 gene (EML4)-ALK receptor tyrosine kinase gene
Autor:
Lauren Fairchild, Jeanne Whalen, Katie D’Aco, Jincheng Wu, Carroll B. Gustafson, Nadia Solovieff, Fei Su, Rebecca Leary, Catarina D. Campbell, O. Alejandro Balbin
In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for gen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::deb5d667e211357b489a5ddbd06c8260
https://doi.org/10.1101/2021.10.27.466159
https://doi.org/10.1101/2021.10.27.466159
Autor:
Jürgen, Wolf, Takashi, Seto, Ji-Youn, Han, Noemi, Reguart, Edward B, Garon, Harry J M, Groen, Daniel S W, Tan, Toyoaki, Hida, Maja, de Jonge, Sergey V, Orlov, Egbert F, Smit, Pierre-Jean, Souquet, Johan, Vansteenkiste, Maximilian, Hochmair, Enriqueta, Felip, Makoto, Nishio, Michael, Thomas, Kadoaki, Ohashi, Ryo, Toyozawa, Tobias R, Overbeck, Filippo, de Marinis, Tae-Min, Kim, Eckart, Laack, Anna, Robeva, Sylvie, Le Mouhaer, Maeve, Waldron-Lynch, Banu, Sankaran, O Alejandro, Balbin, Xiaoming, Cui, Monica, Giovannini, Mikhail, Akimov, Rebecca S, Heist, Jeremy, Cetnar
Publikováno v:
The New England journal of medicine. 383(10)
Among patients with non-small-cell lung cancer (NSCLC),We conducted a multiple-cohort, phase 2 study evaluating capmatinib in patients withA total of 364 patients were assigned to the cohorts. Among patients with NSCLC with aCapmatinib showed substan
Autor:
Tiina Kirsilae, Sylvia Zhao, Ralph Tiedt, Filip de Vos, Andrew B. Lassman, O. Alejandro Balbin, Juan Manuel Sepúlveda, Wolfgang Wick, Yi Cheng, Martin J. van den Bent, Sergio Vicente, W. K. Alfred Yung, Jordi Rodon, Analia Azaro, Hefei Zhang, Ghazaleh Tabatabai, Markus Joerger, Patrick Y. Wen
Publikováno v:
Journal of Neuro-Oncology, 146(1), 79. Kluwer Academic Publishers
Journal of Neuro-Oncology
Scientia
Journal of Neuro-Oncology, 146(1), 79-89. Kluwer Academic
Journal of Neuro-Oncology
Scientia
Journal of Neuro-Oncology, 146(1), 79-89. Kluwer Academic
Purpose To estimate the maximum tolerated dose (MTD) and/or identify the recommended Phase II dose (RP2D) for combined INC280 and buparlisib in patients with recurrent glioblastoma with homozygous phosphatase and tensin homolog (PTEN) deletion, mutat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9b36aef64f4e0b95347daf2e23f3245
https://dspace.library.uu.nl/handle/1874/389056
https://dspace.library.uu.nl/handle/1874/389056
Autor:
Chintan Parmar, Rebecca Leary, Aamna AlShehhi, Angad P Singh, Markus Riester, Ben Gustafson, O. Alejandro Balbin
Publikováno v:
Clinical Cancer Research. 27:PR-08
Circulating tumor DNA (ctDNA) fraction has been shown to be a prognostic factor of treatment response in patients with metastatic cancers. However, algorithms that accurately determine ctDNA fraction across purity ranges are still lacking. Commonly u
Autor:
Guoan Chen, Arul M. Chinnaiyan, William R. Lynch, Lei Xiao, Jian Zhang, Shanker Kalyana-Sundaram, Yanli He, Saravana M. Dhanasekaran, Sudhanshu Shukla, Shengbin Bai, Lihui Wang, Yi Lu, Philip W. Carrott, Zhuwen Wang, Weijun Liu, David G. Beer, Andrew C. Chang, Jie Zhang, Jules Lin, O. Alejandro Balbin, Rishindra M. Reddy
Publikováno v:
Oncotarget
We employed next generation RNA sequencing analysis to reveal dysregulated long non-coding RNAs (lncRNAs) in lung cancer utilizing 461 lung adenocarcinomas (LUAD) and 156 normal lung tissues from 3 separate institutions. We identified 281 lncRNAs wit
Autor:
Fabian Von Arx, Fergal Casey, Sonja Tobler, Robert Cozens, Ying Liang, En Li, E. Robert McDonald, John Monahan, Audrey Kauffmann, Chao Zhang, Hans Bitter, Daniel Wyss, Mallika Singh, Edward Lorenzana, Tara L. Naylor, Francesco Hofmann, Rebecca Leary, Peter Atadja, Alice Loo, Fiona Xu, Anupama Reddy, Hongbo Cai, Ernesta Dammassa, Margaret E. McLaughlin, Shannon Chuai, Yun Zhang, Fernando Salangsang, Susmita Chatterjee, Christian Schnell, Stephanie Barbe, Hui Gao, Michael Rugaard Jensen, Youzhen Wang, Nicholas Keen, William R. Sellers, Millicent Embry, O. Alejandro Balbin, John Green, Marion Wiesmann, Joseph Lehar, Francesca Santacroce, Guizhi Yang, Claudia Roelli, Scott D. Collins, Kavitha Venkatesan, Colleen Kowal, Hui Qin Wang, Montesa Patawaran, Angad P Singh, Jason Merkin, Juliet Williams, Walter Tinetto, Roberto Velazquez, Emma Lees, Stephane Ferretti, Ronald Meyer, Nicolas Ebel, Shawn Cogan, Joshua M. Korn, David A. Ruddy, Zongyao Wang, Yan Tang, Derek Y. Chiang, Nancy Pryer
Publikováno v:
Nature Medicine. 21:1318-1325
Profiling candidate therapeutics with limited cancer models during preclinical development hinders predictions of clinical efficacy and identifying factors that underlie heterogeneous patient responses for patient-selection strategies. We established